LAMIVUDINE, NEVIRAPINE, AND STAVUDINE
Clinical safety rating: safe
Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.
Lamivudine and stavudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV-1 reverse transcriptase by incorporating into viral DNA and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing a conformational change and inhibiting its activity.
| Metabolism | Lamivudine is minimally metabolized (about 5-10%) via hepatic glucuronidation, with the remainder excreted unchanged in urine. Stavudine is intracellularly phosphorylated to active triphosphate; it is not extensively metabolized by the liver. Nevirapine is extensively metabolized by CYP3A4 and CYP2B6 isoenzymes. |
| Excretion | Lamivudine: ~71% excreted unchanged in urine (glomerular filtration and active tubular secretion). Nevirapine: ~81% excreted in urine as glucuronide conjugates, <5% unchanged; ~10% in feces. Stavudine: ~40% excreted unchanged in urine (active tubular secretion), with remainder as metabolites. |
| Half-life | Lamivudine: 5-7 hours (prolonged in renal impairment). Nevirapine: 25-30 hours (terminal, autoinduction reduces early half-life; significant accumulation). Stavudine: 1.0-1.6 hours (short; prolonged in renal impairment). |
| Protein binding | Lamivudine: <36% (minimal binding to albumin). Nevirapine: ~60% (primarily albumin). Stavudine: <5% (negligible binding). |
| Volume of Distribution | Lamivudine: 1.3-1.5 L/kg (distributes into total body water; penetrates CSF). Nevirapine: 1.2-1.5 L/kg (extensive tissue and CSF penetration). Stavudine: 0.41-0.74 L/kg (distributes into total body water; limited CNS penetration). |
| Bioavailability | Lamivudine: 86-88% (oral). Nevirapine: >90% (oral). Stavudine: 86% (oral). |
| Onset of Action | Oral: Lamivudine achieves steady-state in 1-2 weeks; Nevirapine reaches steady-state in 2-4 weeks; Stavudine achieves steady-state in 1-2 weeks. Antiviral effects observed within days to weeks. |
| Duration of Action | Lamivudine: 12 hours (dosing interval). Nevirapine: 12 hours (dosing interval; long half-life allows twice-daily dosing). Stavudine: 12 hours (dosing interval; short half-life requires twice-daily dosing). Clinical duration extends with adherence. |
Lamivudine 150 mg, nevirapine 200 mg, and stavudine 30 mg (or 40 mg if weight ≥60 kg) orally twice daily for HIV treatment in adults.
| Dosage form | TABLET |
| Renal impairment | Lamivudine: For CrCl 30-49 mL/min, dose 150 mg once daily; CrCl 15-29 mL/min, first dose 150 mg, then 100 mg once daily; CrCl 5-14 mL/min, first dose 150 mg, then 50 mg once daily; CrCl <5 mL/min or hemodialysis, first dose 50 mg, then 25 mg once daily. Stavudine: For CrCl 26-50 mL/min, reduce dose by 50%; CrCl 10-25 mL/min, reduce dose by 75%; CrCl <10 mL/min or hemodialysis, reduce dose by 75% and give after dialysis. Nevirapine: No adjustment needed in renal impairment; not removed by dialysis. |
| Liver impairment | Nevirapine is contraindicated in Child-Pugh class B or C; should not be used in moderate to severe hepatic impairment. Lamivudine and stavudine: No specific adjustment; use with caution, monitor for toxicity. |
| Pediatric use | Weight-based dosing for children ≥3 months: Lamivudine 4 mg/kg (max 150 mg) twice daily; nevirapine 200 mg/m2 (4-7 mg/kg) once daily for 14 days, then twice daily; stavudine 1 mg/kg (max 40 mg) twice daily for weight <30 kg, and 30 mg twice daily for weight 30-59 kg, 40 mg twice daily for weight ≥60 kg. |
| Geriatric use |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.
| FDA category | Animal |
| Breastfeeding | Lamivudine, nevirapine, and stavudine are excreted into human breast milk. The milk-to-plasma ratio for lamivudine is approximately 0.6, for nevirapine is approximately 0.6-0.7, and for stavudine is approximately 0.6. Breastfeeding is not recommended in high-resource settings due to the risk of transmission of HIV-1 and potential infant toxicity. In resource-limited settings where breastfeeding is essential, the benefits of preventing maternal disease progression may outweigh risks, but guidelines often recommend avoidance of nevirapine due to risk of hepatotoxicity in the nursing infant. |
■ FDA Black Box Warning
Hepatotoxicity: Severe, life-threatening hepatotoxicity, including fulminant hepatitis and hepatic failure, has been reported with nevirapine. Patients with higher CD4+ cell counts are at increased risk. Lactic acidosis and severe hepatomegaly with steatosis have been reported with lamivudine and stavudine, including fatal cases.
| Common Effects | Peripheral neuropathy |
| Serious Effects |
Hypersensitivity to any component; coadministration with drugs that depend on CYP3A4 for clearance and for which elevated plasma levels are associated with serious adverse events; severe hepatic impairment (Child-Pugh class C); patients with baseline CD4+ count >250 cells/mm³ in women or >400 cells/mm³ in men due to increased risk of hepatotoxicity with nevirapine.
| Precautions | Monitor liver function tests closely, especially during the first 18 weeks of nevirapine therapy. Patients should be observed for signs of hepatotoxicity and lactic acidosis. Dose adjustments may be needed for renal impairment (lamivudine, stavudine). Avoid use with other hepatotoxic drugs. Nevirapine can cause severe skin reactions including Stevens-Johnson syndrome. |
Loading safety data…
| No specific age-based adjustments; use caution due to increased risk of renal, hepatic, or cardiac dysfunction; monitor renal function and adjust doses accordingly for lamivudine and stavudine based on CrCl. |
| Teratogenic Risk | Nevirapine is classified as FDA Pregnancy Category C. Lamivudine and Stavudine are Category C. First trimester: lamivudine and stavudine do not show increased malformation risk based on human data; nevirapine has been associated with a possible increased risk of teratogenicity in some studies, but data are conflicting. Second and third trimesters: nevirapine use is associated with a risk of hepatotoxicity and Stevens-Johnson syndrome, especially in women with higher CD4 counts (>250 cells/μL) initiating therapy. All three drugs cross the placenta. There is a risk of mitochondrial toxicity and lactic acidosis in infants exposed in utero to nucleoside reverse transcriptase inhibitors. The Antiretroviral Pregnancy Registry reports no major teratogenic signals for lamivudine or stavudine. |
| Fetal Monitoring | Monitor maternal liver function tests (especially with nevirapine), complete blood count, renal function, serum lactate, and lipase. For fetal monitoring: serial ultrasounds for growth and anatomy including cardiac assessment. Perform HIV-1 RNA viral load and CD4 count monitoring every 1-2 months. Monitor for signs of lactic acidosis and mitochondrial toxicity in the infant. At delivery, assess for anemia and hyperbilirubinemia in the newborn. Long-term follow-up for potential neurodevelopmental and mitochondrial effects is recommended. |
| Fertility Effects | No significant adverse effects on fertility have been reported for lamivudine, nevirapine, or stavudine in human studies. Animal studies show no impairment of fertility. However, stavudine may cause lipodystrophy and metabolic disturbances that could indirectly affect fertility. HIV infection itself can impair fertility, and effective antiretroviral therapy often improves fertility outcomes. |